Compugen Ltd

From Code to Cure®: A leader in predictive drug target discovery advancing a pipeline of #immunotherapies for cancer. $CGEN

[Oxford Global @OGConferences]

The Therapeutic Modulation of Cytokines with Pierre Ferré, VP of Pre-Clinical Development, Compugen https://t.co/4PxRtWRkuZ

[Nucleai @nucleai_ai]

We're thrilled to welcome Dr. Granit from @CompugenLtd to #NucleaiAcademy lecture series. Dive deep into the transformative world of #SpatialTranscriptomics & it's pivotal role in tumor biology research https://t.co/C69V4m541S #Immunotherapy #PrecisionOncology #SpatialBiology

[Compugen Ltd @CompugenLtd]

Listening to "Applying multiomics to novel target discovery in immuno-oncology" at https://t.co/08CdF0yjU4

[LifeSci Advisors @LifeSciAdvisors]

Join us on May 23rd at 12pm ET for a KOL webinar with @CompugenLtd, featuring Drew Pardoll, MD, PhD (@dpardol1) discussing Compugen's differentiated DNAM-1 axis hypothesis, suggesting the simultaneous blockade of PVRIG, TIGIT and PD-1. Register here: https://t.co/eoJfHbPSGB $CGEN

[LifeSci Advisors @LifeSciAdvisors]

Join us on May 23rd at 12pm ET for a KOL webinar with @CompugenLtd, featuring Drew Pardoll, MD, PhD (@dpardol1) discussing Compugen's differentiated DNAM-1 axis hypothesis, suggesting the simultaneous blockade of PVRIG, TIGIT and PD-1. Register here: https://t.co/eoJfHbQqw9 $CGEN

[Proactive USA @proactive_NA]

$CGEN Compugen says it is pioneering a 'computational discovery approach' to cancer immunotherapy https://t.co/tya99S3vAb @CompugenLtd #CGEN

[Compugen Ltd @CompugenLtd]

Our CEO Anat Cohen-Dayag speaks to @KarenJagoda about the computational approach powering our discovery and clinical development and its promise for cancer patients who've exhausted all other treatment options. Listen: https://t.co/M9UfYT3H4C #Immunooncology #TIGIT #PVRIG #DNAM1

[Roy Granit @rgranit]

I’m excited to share that our recent research findings on the accurate #singlecellanalysis of #PVRIG and its corrected #genemodel are now available on @biorxiv_bioinfo 🧬📢https://t.co/4wSFTWGkbv

[Compugen Ltd @CompugenLtd]

Proud of our CEO Dr. Anat Cohen-Dayag. Anat recently sat down w/ @Gold_pharma to discuss her career journey and @CompugenLtd's transformation to a clinical-stage cancer #immunotherapy company and pioneer in computational target discovery. Check out the article! #LeadershipMatters

[EMJ GOLD @EMJ_GOLD]

In GOLD's '5 minutes with Anat Cohen-Dayag, CEO, Compugen', Anat shares her thoughts on the challenges facing pharma CEOs today, the value of mentorship and why organisations need a diverse range of personality types.

Read here: https://t.co/Pn5gL2cR5u

#compugen #mentorship

[Compugen Ltd @CompugenLtd]

Honored to be named Best Clinical-Stage Immuno-oncology Development Company by @Global_H_Pharma. This award recognizes the promise of our work on the DNAM-1 axis hypothesis, which positions us to lead in this new area of cancer immunotherapy. https://t.co/GobtQfDzOb #DNAM1 #TIGIT

[Compugen Ltd @CompugenLtd]

CEO @AnatDayag spoke with @NoCamels about the inequalities #womenintech face, including fewer leadership roles. We’re grateful for her dedication and are excited for our future with her at the helm. Read more: https://t.co/4rgOetMIbD #womeninscience

[Compugen Ltd @CompugenLtd]

Compugen Still Confident Of Its TIGIT Strategy Despite Roche’s Setbacks https://t.co/VGYOWsPAvI

[Compugen Ltd @CompugenLtd]

Compugen’s VP for Preclinical Development, will be presenting on PVRIG and TIGIT immune checkpoint blockade in cancer: Emerging translational data from clinical trials at the upcoming @congress_AIS #immunotherapy #immunooncology #ais2022

[Compugen Ltd @CompugenLtd]

Compugen’s Henry Adewoye and Ari Krashin are delighted to be participating at this year’s JMP Securities LLC Life Sciences Conference in New York City. You can listen in live to the fireside chat moderated by Reni Benjamin by going to https://t.co/FujYLJ2jqx #checkpoint

[Compugen Ltd @CompugenLtd]

Compugen's @AnatDayag and Ari Krashin are delighted to be participating at this year’s #JefferiesHealthcare Conference in New York City. You can listen in live to the fireside chat moderated by Chris Howerton, Ph.D. on https://t.co/YADMoFj6xE
#jefferies #immunotherapy

[Compugen Ltd @CompugenLtd]

Compugen’s SVP, Research and Drug Discovery, Eran Ophir, will present at the upcoming Biomed Israel Conference in Tel Aviv on May 12th.
Learn more about the event on https://t.co/6Y7Wvu6ihq

[Compugen Ltd @CompugenLtd]

Today, Compugen's Roy Granit is presenting at the Keystone Symposium: Cancer Immunotherapy: Decoding the Cancer Immunity Interactome.
You can find details on Roy’s presentation on https://t.co/yDUueAf0Me

[Compugen Ltd @CompugenLtd]

Today, Compugen's Roy Granit is presenting at the Keystone Symposium: Cancer Immunotherapy: Decoding the Cancer Immunity Interactome.
You can find details on Roy’s presentation on https://t.co/yDUueAf0Me

[Compugen Ltd @CompugenLtd]

Today we will be presenting at the @oppenheimer 32nd Annual Healthcare Conference #OpcoHC22. For more details on the presentation click here: https://t.co/a2y3CTvJM8 and be sure to check out the #webcast here: https://t.co/saOurcmidR

[Compugen Ltd @CompugenLtd]

On #InternationalWomensDay we are proud to have women representing 53% of our workforce and to be led by an inspiring female President and CEO, Anat Cohen-Dayag @AnatDayag #BreakTheBias #IWD2022